Sep02

Just Released: Updated MPT Product Development Database

Wednesday, 02 September 2020

The IMPT recently released its updated MPT Product Development Database. The IMPT Secretariat conducted the annual update process between February and June of 2020 and launched the updated database in July 2020.

Resources used to update the database included: product developer updates, published peer-reviewed literature, relevant scientific conferences, and publicly available funding data.

The following benchmarks were used as inclusion criteria: availability of preclinical or clinical test results suggestive of efficacy for two or more indications (pregnancy, HIV prevention, other STI prevention). Additionally, as of 2020, for a product to be included in the database it must be in active development and have current funding. Per suggestions from MPT stakeholders, product developers were requested to report on specific funding mechanisms. This information was added to the database for each product in order to better reflect the status of the product development landscape. The database is also updated on a rolling basis throughout the year when the Secretariat is informed of MPT updates. Click here to learn more about our updated inclusion criteria and methodology.

As of June 2020, there are 24 MPT product candidates in the searchable database. Key findings regarding the current pipeline:

  • Most of the product candidates are in pre-clinical stages of development (16), with a smaller number in clinical trials (8) and only two in late clinical stages (III or IV) of development.
  • Over half of the product candidates combine contraception and HIV prevention (14), while many also combine contraception or HIV prevention with non-HIV anti-infective indications (e.g. HSV-2, chlamydia) (16). A smaller subset of products combine HIV and other STI prevention without contraception (7).
  • There are a number of non-hormonal contraceptive (nonHC) MPTs in pre-clinical or clinical development (7).
  • The range of delivery methods continues to shift, and currently includes the following: intravaginal rings (IRVs), fast dissolving inserts, vaginal and rectal gels, vaginal films, pills, patches, and implants.

The IMPT celebrates the innovation and increasing diversity of options that characterize the current MPT pipeline, and recognizes this as an exciting time for the field. We also acknowledge finite resources and technical challenges that can act as roadblocks to advancing promising pre-clinical products through the pipeline to clinical stages of development. This can be observed in the proportion of the pipeline that is in pre-clinical development compared to clinical stages, particularly late clinical stages. To see our recommendations for addressing this gap, visit the commentary published in the Contraceptive Special Issue of the journal Biology of Reproduction that we co-authored with the WHO, FHI 360, Magee-Women’s Research Institute and Foundation, the University of Pittsburgh, and UCSF.

The IMPT Secretariat also updated the downloadable MPT Product Pipeline Table organized by indication combination and added a new table organized by delivery method. Additionally, the updated MPT Database landing page now also features a menu of MPT product types, organized by delivery method, that are easy to browse. As always, the database homepage still features a feedback button where we invite our partners and colleagues to share new and updated product information that is not listed.

Your active engagement with the database is vital to ensuring that it remains an important and up-to-date resource for informing progress in the MPT field, with the ultimate goal of accelerating women’s access to a range of comprehensive prevention options.

About the Author

Susanna Moore, IMPT Program Associate

Susanna joined CAMI Health as Program Associate in May 2020. In this role, she provides project management and support for IMPT Secretariat initiatives, such as the IMPT Resource Hub, the MPT Product Development Database, IMPT online communications, and partner engagement, among others. Susanna brings with her over 15 years of experience in women’s global health and international development. Prior to joining CAMI Health, Susanna had spent six years with other global health programs at the Public Health Institute, most notably as Program Manager for GOJoven International Program and Deputy Chair for the IBP Initiative, an international consortium housed at the WHO that identifies and promotes evidence-based and proven effective practices to improve family planning/reproductive health outcomes worldwide.

Read More
The IMPT is the first & only initiative dedicated to advancing the field of multipurpose prevention technologies (MPTs), products that combine HIV prevention, other STI prevention, and contraception.

IMPT Secretariat
1750 Howe Avenue, Suite 550
Sacramento, CA 95825
IMPT@cami-health.org

The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, a social impact organization dedicated to improving the health of women and their families worldwide. CAMI Health is housed at the Public Health Institute (PHI).

This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.
© Copyright 2020, Public Health Institute / CAMI Health / IMPT Secretariat. All rights reserved.